Shares of Eagle Pharmaceuticals Inc (NASDAQ:EGRX) have received an average rating of “Hold” from the six research firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $63.67.
Several equities analysts have weighed in on EGRX shares. Piper Jaffray Companies reiterated a “buy” rating and issued a $75.00 target price on shares of Eagle Pharmaceuticals in a report on Friday, October 27th. Mizuho reiterated a “sell” rating and issued a $37.00 target price on shares of Eagle Pharmaceuticals in a report on Wednesday, November 8th. Royal Bank of Canada reiterated an “outperform” rating and issued a $75.00 target price (down from $81.00) on shares of Eagle Pharmaceuticals in a report on Thursday, November 9th. BidaskClub upgraded shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, December 2nd. Finally, ValuEngine lowered shares of Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, December 31st.
Large investors have recently bought and sold shares of the business. Municipal Employees Retirement System of Michigan boosted its holdings in Eagle Pharmaceuticals by 68.1% in the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 3,210 shares of the specialty pharmaceutical company’s stock valued at $191,000 after purchasing an additional 1,300 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in shares of Eagle Pharmaceuticals in the 2nd quarter worth approximately $276,000. Cubist Systematic Strategies LLC acquired a new position in shares of Eagle Pharmaceuticals in the 2nd quarter worth approximately $292,000. Schroder Investment Management Group acquired a new position in shares of Eagle Pharmaceuticals in the 3rd quarter worth approximately $219,000. Finally, Foundry Partners LLC acquired a new position in shares of Eagle Pharmaceuticals in the 3rd quarter worth approximately $224,000.
Eagle Pharmaceuticals (EGRX) opened at $56.81 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.15 and a current ratio of 5.30. The firm has a market cap of $836.66, a PE ratio of 9.16 and a beta of 1.25. Eagle Pharmaceuticals has a 52-week low of $45.05 and a 52-week high of $97.15.
Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported $1.07 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.50. Eagle Pharmaceuticals had a net margin of 36.95% and a return on equity of 62.60%. analysts anticipate that Eagle Pharmaceuticals will post 2.23 EPS for the current fiscal year.
WARNING: “Eagle Pharmaceuticals Inc (EGRX) Receives Average Rating of “Hold” from Brokerages” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/17/eagle-pharmaceuticals-inc-egrx-receives-average-rating-of-hold-from-brokerages.html.
About Eagle Pharmaceuticals
Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.